Trajan Group Holdings Ltd · ASX:TRJ
Trajan — FY2026 Earnings Presentation
22 slides from Trajan's earnings presentation, Aug 27, 2026
Slide 1: FY26 Results
www.trajanscimed.com FY26 Results July 01, 2025 – June 30, 2026 Stephen Tomisich, CEO and Simon Billingham, Interim CFO – Webcast 27 August 2026
Slide 2: Trajan Scientific and Medical Snapshot
Trajan Scientific and Medical Snapshot Operating Segments A global developer and manufacturer of analytical and life science Components & Consumables products and devices, founded in 2011 to have a positive impact on Recurrent Revenue; multiple channels to market; regional agility. human wellbeing.
Slide 3: FY26 Financial Summary
e ee s sah = |. ¥ " Enriching Personal Health Through Scientific Tools and Soluti' tT + [ = - — : ? si @TRA , JAN | Science that benefits people
Slide 4: FY2026 Financial Summary
FY2026 Financial Summary KEY POINTS REVENUE & EARNINGS FINANCIAL POSITION • Revenue: Reported revenue declined due to forex volatility. Underlying H2 FY26 revenue was Group Revenue $161.4M Cash $ 12.6M impacted by circa $5.0M due to AUD appreciation. [PCP: $166.5M] Down 3.1% [PCP $11.9M] Up 6.5% • n
Slide 5: FY26 Overview
FY26 Overview Resilient Performance Building Momentum in H2 FY26 Mixed Trading Conditions • External margin pressure volatility and “in-region, for-region” transition impacted full year result • Robust Components & Consumables, demonstrated stability in our major business segment • Capital Equipment
Slide 6: Impacts on FY26 Results
Impacts on FY26 Results Headwinds • Macroeconomic environment • Government funding delays impacted sales. • Restructures in Pharma and Food accounts in FY26 prevented some planned Capital Equipment purchases. • General slow down in growth across the Food sector most likely linked to volatility of th
Slide 7: $11M nEBITDA was Predicted for H2
$11M nEBITDA was Predicted for H2 • The H2 nEBITDA result of $8.1M** showed an uplift of 61.8% compared to the first half result ($5.0M nEBITDA in H1). • When FX adjusted, we achieved $10.5M** nEBITDA in H2, a 109.3% uplift Predicted H2 nEBITDA bridge: • baseline nEBITDA • Resource reductions, $0.8M
Slide 8: Impact of Improvements in H2
Impact of Improvements in H2 Tangible operational initiatives were realised: • Project Neptune cost reductions in headcount and facilities gave an uplift of $1.2M in H2. • Reduction in Corporate Services headcount achieved a further uplift of $1.2M in H2. • Pricing actions effective 01 January 2026
Slide 9: Evidence of Building Momentum
Evidence of Building Momentum Uplift in nEBITDA across the group during FY26 • As the actions took hold, we saw momentum build, despite the adverse impact of AUD appreciation. Trajan FY26 nEBITDA by Quarter $6,000 $5,000 $4,000 AUD $K $3,000 $2,000 $1,000 $- Q1 Q2 Q3 Q4 9
Slide 10: Demonstration of Consistent Growth
Demonstration of Consistent Growth Resilience in, Components and Consumables, our largest Business Segment is evident. Annualised revenue, at monthly resolution and fixed Forex rates, reveals that post destocking (March 2024), growth rate is back to normal. Components & Consumables Sales, Moving Ann
Slide 11: Operating Segments
Operating Segments
Slide 12: Components & Consumables
Components & Consumables • Fixed FX basis sales growth +2.2% for FY26; H2 up 3.0% vs H1, reflecting continued underlying growth. Net Revenue Gross Margin nEBITDA* • Margin impacted by H1 in-region, for-region $102.6M 39.3% down 2.3pts $32.1M down 7.9% investments; recovered from H1 margin of 37.5% 2
Slide 13: Capital Equipment
Capital Equipment 30.2 29.9 28.7 29.1 27.1 27.6 26.3 23.9 6.7 5.3 5.1 5.6 4.6 4.1 4.8 3.7 Capital Equipment • Revenue impacted by softer market conditions; Revenue nEBITDA • low government funding in North America, and • the response of food and pharmaceutical companies to volatile macroeconomic con
Slide 14: Disruptive Technologies
Disruptive Technologies 3.5 10.0 3.1 3.0 2.9 3.0 8.0 2.7 2.8 2.6 2.5 6.0 2.2 2.2 2.0 4.0 1.5 2.0 -0.5 -0.3 -0.3 1.0 -1.0 - -2.3 -2.1 -2.0 0.5 -2.9 -2.0 - -4.0 Disruptive technolgoies Revenue nEBITDA • Stronger FY26 performance across all financial metrics, underpinned by sustained microsampling sale
Slide 15: Cashflow Summary
Cashflow Summary • Cash conversion reflects strategic working capital investment in: FY2026 FY2025 ($M) ($M) • Supply chain resilience and support for growth across key Normalised EBITDA* 13.2 15.5 international markets. Income tax payments (0.8) (0.4) • Timing of our ERP implementation in Germany,
Slide 16: FY27 Outlook
FY27 Outlook Outlook • We expect nEBITDA momentum to continue. • Note; one-off restructuring costs are part of that progression. • The cost base will continue to reduce. • The currency risk remains, however: • We have hedging at sub USD $0.70c through to June 2027. • As we progress offshore manufact
Slide 17: FY27 Guidance
FY27 Guidance Given improved momentum seen since Q2 FY26, even at current exchange rates, the company expects to achieve: • Mid-single digit organic revenue growth in FY27 and • Double-digit nEBITDA growth in FY27 over pcp* (* pcp prior comparable period) We anticipate to provide more specific guida
Slide 18: Fundamentals
Fundamentals TRAJAN | =
Slide 19: Ongoing, Stable and Strong Business Foundation
Ongoing, Stable and Strong Business Foundation - Built for Scale and Changing Market Trends Diversified Global Platform Trusted Market Position Innovation & Long-Term Value Creation 19
Slide 20: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 27th August 2026. The information in the presentation is provided for information purposes only, is in summary form and does not
Slide 21: Q&A
a 1 TRAJAN Science that benefts/peopid www.trajanscimed.com
Slide 22: Thank you
Thank you www.trajanscimed.com22